Treatment with JHU-083 potentiated the antitumor effect of the EGFR peptide vaccine (EVax) by increasing tumor infiltration of CD8+ T cell and CD4+ Th1 cells and inhibiting immune suppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), granulocytic myeloid-derived suppressor cells (G-MDSCs), and tumor-promoting CD4+ Th17 cells in the syngeneic lung tumor models carrying human epidermal growth factor receptor EGFRL858R mutation and transgenic EGFRL858R-driven murine lung cancer model [98]. The gene discussed is CD4; the disease is lung cancer.